Biotech's Billion Dollar Bet: ADARx Pharmaceuticals Takes Aim at Rare Diseases ADARx Pharmaceuticals' IPO filing has reignited interest in the biotech sector, with a valuation target of up to $1. 74 billion.
The company is joining a growing list of companies seeking to tap into the lucrative market for rare disease treatments.
ADARx's technology focuses on RNA based therapies, which have shown promise in addressing complex conditions affecting the immune system, kidneys, cardiovascular health, and neurological functions.